Cagrilintide and dual/triple receptor agonists
EhBuddy Research-Grade Cagrilintide — Available in 10mg, 5mg
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, studied in combination with Semaglutide (CagriSema) for obesity research. Amylin receptor activation synergizes with GLP-1 pathways to drive satiety, reduce caloric intake, and improve body composition. Phase 3 REDEFINE trials show body weight reductions potentially exceeding 25%.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.

You must be 18 or 19 years of age depending on the age of majority in your province and a licensed research professional.
All products — including research peptides, injectable steroids (testosterone, nandrolone, boldenone, trenbolone, etc.), oral steroids, and oral research compounds — are sold strictly for laboratory and scientific research purposes only. Not for human or veterinary consumption. No dosing instructions are provided.
We adhere to all provincial and federal laws in Canada governing Research Only Chemical sales.
By clicking "I Agree" you confirm you have read and accepted the Terms and Conditions above.